

**Identity:**

Title: Professor  
 Family Name(s): Petrie  
 First Name(s): Mark  
 Age: 54

**Photo:****Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board member

**Place of work**

*If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.*

Institute/organisation:	University of Glasgow
Department:	Cardiology
Address:	126 University Avenue
Post code / Zip:	G12 8QQ
Country:	United Kingdom

**General Curriculum Vitae (500 words max)**

*Please also include your H index and top 5 to 10 publications in the last 5 years*

H Index Google scholar 87

- 1) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, **Petrie MC**; STEP-HFpEF Trial Committees and Investigators. **N Engl J Med.** 2023 Sep 21;389(12):1069-1084.
- 2) Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, Arnold S, Dixon LJ, Edwards RJ, De Silva K, Spratt JC, Conway D, Cotton J, McEntegart M, Chiribiri A, Saramago P, Gershlick A, Shah AM, Clark AL, **Petrie MC**; Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. REVIVED-BCIS2 Investigators. **N Engl J Med.** 2022 Aug 27.
- 3) Kalra PR, Cleland JGF, **Petrie MC**, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. **Lancet.** 2023 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5.
- 4) Pfeffer MA, Claggett B, Lewis EF, .. **Petrie MC**, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction. **N Engl J Med.** 2021 Nov 11;385(20):1845-1855.
- 5) Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, Murphy CL, Ford TJ, Sidik N, McEntegart MB, Lang NN, Jhund PS, Campbell RT, McMurray JJV, **Petrie MC**. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients

With Heart Failure With Preserved Ejection Fraction. **JAMA Cardiol.** 2021 Oct 1;6(10):1130-1143.

- 6) McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozd J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, **Petrie MC**, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. **N Engl J Med.** 2019 Nov 21;381(21):1995-2008.
- 7) **Petrie MC**, Verma S, .. Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. **JAMA.** 2020 Mar 27.

**Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society**  
*150 words maximum*

I am currently a su generis non-voting member of the Heart Failure Association Board. I chair the Heart failure with Preserved Ejection Fraction group. I have been a member of the Executive Committee of the HFA's Peripartum Cardiomyopathy Committee since its inception in 2009 and have driven this alongside other key individuals (Profs Sliwa and Bauersachs). This has been one of the most successful HFA groups resulting in 14 papers in excellent journals. The HFA PPCM team has worked across many low- and middle- income countries with fantastic HFA collaboration and engagement. I led the HFA's 2018 diabetes highly cited consensus paper alongside Professor Severovic. I have presented and chaired many HFA sessions at the annual meeting. I have also contributed to other HFA papers on obesity, hypertension and renal function among others. I am a Board member of the British Society for Heart Failure and chair the Research Committee.

**Why are you motivated to join the HFA Board or Nominating Committee?**  
*150 words maximum*

I am motivated to join the HFA Board to work with international colleagues to advance the HFA's efforts to drive quality improvement in the care of people with HF as well to further advance the diagnosis and treatment of heart failure. I am especially keen to champion teamwork in heart failure management working with nurses and pharmacists as well as patient groups. I am enthused by colleagues already engaged with the HFA but am very keen to identify and welcome new faces from a variety of countries to join the HFA's efforts. I am keen to continue to drive and collaborate to produce excellent scientific output.

**How will you combine your HFA position with your daily clinical/research workload?**  
*80 words maximum*

If successful I will prioritise HFA's work alongside my clinical and research work. I now hold an academic position (following many years as a full-time clinician) which allows me flexibility to achieve HFA goals.